share_log

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Director Curran Terrie

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Director Curran Terrie

Arcutis Biotherapeutics | 4:持股變動聲明-董事 Curran Terrie
美股SEC公告 ·  11/13 18:47

Moomoo AI 已提取核心訊息

Terrie Curran, a reporting person associated with Arcutis Biotherapeutics, Inc. [ARQT], completed a sale of 8,687 shares of common stock on November 11, 2024. The transaction was executed in the open market at a price of $10.8482 per share, resulting in a total sale value of approximately $94,238.31. Following the sale, Curran's direct holdings in the company amount to 10,139 shares of common stock.
Terrie Curran, a reporting person associated with Arcutis Biotherapeutics, Inc. [ARQT], completed a sale of 8,687 shares of common stock on November 11, 2024. The transaction was executed in the open market at a price of $10.8482 per share, resulting in a total sale value of approximately $94,238.31. Following the sale, Curran's direct holdings in the company amount to 10,139 shares of common stock.
Terrie Curran,一位與Arcutis Biotherapeutics, Inc. [ARQT]相關的報告人,於2024年11月11日完成了8,687股普通股的出售。這筆交易是在公開市場以每股10.8482美元的價格進行的,交易總值約爲94,238.31美元。出售後,Curran在公司的直接持股總數爲10,139股普通股。
Terrie Curran,一位與Arcutis Biotherapeutics, Inc. [ARQT]相關的報告人,於2024年11月11日完成了8,687股普通股的出售。這筆交易是在公開市場以每股10.8482美元的價格進行的,交易總值約爲94,238.31美元。出售後,Curran在公司的直接持股總數爲10,139股普通股。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息